Orasure Technologies, Inc. · NASDAQ:OSUR
Orasure Technologies — Investor Day (November 2016)
99 slides from Orasure Technologies's investor day presentation, Nov 29, 2016
Slide 1: OraSure Technologies Analyst Day
OraSure Technologies Analyst Day November 29, 2016 Nasdaq MarketSite
Slide 2: Agenda
Agenda • Welcome and introductions • Infectious Disease – HCV Country-Wide Elimination Programs – HIV Self-Testing – R&D: Emerging Diseases -Ebola, Zika – Tuberculosis (TB) • Molecular – Personal Genomics – Microbiome – R&D: Sample Optimization • Financial review / Business Development • Summary
Slide 3: Forward-looking statements
Forward-looking statements These slides and the associated presentation contain certain forward-looking statements, including statements with respect to revenues, earnings, technology, new products, product performance, markets, clinical development, regulatory filings and approvals, and business pl
Slide 4: Welcome and introductions
Welcome and introductions Tony Zezzo Executive Vice President, Business Unit Lead, Infectious Disease Mike Reed, Ph.D. Senior Vice President, Research & Development and Chief Science Officer Cassandra Kelly-Cirino, Ph.D. Vice President, Infectious Disease TB and Emerging Diseases Program Lead Brian
Slide 5: Our company vision
Our company vision Empower healthcare providers and patients worldwide to improve global health through access to accurate, essential information. We will accomplish this through a deep understanding of our customers’ needs and a commitment to innovative infectious disease and molecular solutions.
Slide 6: Core strategic growth pillars
Core strategic growth pillars Grow Molecular business Grow Infectious Disease business Driving unprecedented global access to our existing and new Infectious Disease diagnostics Leveraging the strength of our Molecular business into new growth markets, with existing and new technology
Slide 7: Strong platform foundation for growth
Strong platform foundation for growth 2004 2011 2005 2006 2007 20102002 2008 2009 2012 2013 2014 2015 2016 2017 Infectious Disease Molecular * *OraQuick Self-Test is currently under review †OraQuick Zika is currently under development 7 Strong platform foundation for growth 2004 2011 2005 2006 2007
Slide 8: Core growth strategies
Core growth strategies Molecular • Expand beyond sampling to offer incremental value from collection through to reporting via complementary products and services • Leverage early wins in Asia to replicate success in US • Focus on standardization and weaving Microbiome into genomics research customer
Slide 9: HCV Country-Wide Elimination Programs
HCV Country-Wide Elimination Programs Tony Zezzo Executive Vice President Business Unit Lead, Infectious Disease OraSure Technologies, Inc.
Slide 10: HCV opportunities
HCV opportunities • 170 million people infected globally, 4-5 million people infected in U.S. – The majority of HCV infection remains undiagnosed • Approved drugs, and those in the pipeline, are driving demand for increased diagnoses and the number of patients initiating therapy • Significant reduct
Slide 11: OraQuick HCV Rapid Antibody Test
OraQuick® HCV Rapid Antibody Test Quality matters • Accurate – sensitivity and specificity comparable to lab-based immunoassays • Versatile -reach patients outside traditional laboratory testing channels • Simple – extremely easy to use three step process; use with oral fluid outside U.S. • 20 minut
Slide 12: HCV product revenue 2013-2016
HCV product revenue 2013-2016 Overall Growth Product Revenue Growth HCV Product Revenue by Segment 2013 Domestic International 56%44% • Product revenue growth of 270% • CAGR of 28.2% • Historical revenue drivers: – Domestic Public Health – Asia and Large International NGO • Future revenue drivers: –
Slide 13: Eliminate viral Hepatitis by 2030
Eliminate viral Hepatitis by 2030 WHO leading effort to eliminate viral hepatitis by 2030 36 countries with national plans to combat hepatitis 33 countries formulating national plans Source: WHO, Combating Hepatitis B and C to Reach Elimination by 2030, May 2016 13
Slide 14: HCV program opportunities
HCV program opportunities (examples) Country 1 • Country-wide testing campaign over 12 months • $18 million in value, 90% HCV tests • Multi-million test kit purchase with additional purchase option Country 3 • Outreach and remote testing initiative • Initial order shipped, additional orders anticipa
Slide 15: Excellent growth prospects
Excellent growth prospects • Recognized bodies (WHO) have prioritized Hepatitis and Hepatitis C for elimination • Price of HCV therapy is significantly reduced in developing countries • Large scale test and treat pilots and country elimination programs are being executed • Recognition that all test
Slide 16: HIV Self-Testing
HIV Self-Testing Tony Zezzo Executive Vice President Business Unit Lead, Infectious Disease OraSure Technologies, Inc.
Slide 17: The need and opportunity
The need and opportunity • ~100MM HIV rapid tests are deployed annually, funded largely by donor agencies • 36.7 million people globally were living with HIV (end 2015), only half of those individuals know their status • The majority of undiagnosed individuals have limited or no access to health ser
Slide 18: State of HIV self-testing
State of HIV self-testing • The first studies conducted by the London School of Hygiene and Tropical Medicine • Other studies followed by several notable organizations • Two important outcomes developed: – More people chose to test when offered a self test – OraQuick was used in all studies for its
Slide 19: The OraQuick HIV self-test
The OraQuick® HIV self-test Self-test product contains: Standard OraQuick device and vial, single use stand and a package insert placed in an over-pouch for personal use/carry. Over-pouched for single use Standard device/vial Package insert + single use stand
Slide 20: OraQuick and self-testing competitive advantage
OraQuick and self-testing Competitive advantage • OraQuick track record of success • Endorsement from leading KOLs • Ease of use and oral fluid matrix • Foundation and validation studies well underway
Slide 21: State of HIV self-testing: WHO/UNITAID landscape report
State of HIV self-testing WHO/UNITAID release landscape report on Rapid HIV self-testing • Market for HIV self testing tools is clearly growing – Drivers are replacement, frequency of testing and uptake of testing – Early estimates indicate self testing could easily reach 23M tests annually • Additi
Slide 22: Key progress to date
Key progress to date • UNITAID/PSI STAR program phase 1 initiated in Zimbabwe, Malawi and Zambia • Shipped over 400K tests to pilot countries • Additional studies initiated in 6 countries with early stage interest • WHO submission received 10/7/2016 • WHO pre-qualification opens up funding through v
Slide 23: Next steps
Next steps • Complete Phase 1 (750K units) of UNITAID/PSI initiative and prepare for Phase 2 (1.9M units) • Continue ongoing discussions with additional 6 countries to deploy once WHO prequalification is achieved • Initiate studies in additional countries
Slide 24: Summary
Summary • Major funding organizations are showing high interest in self-testing • Volume growth will be significant over the next few years • The OraQuick HIV Self-test is very well positioned as the easiest, high quality, oral fluid rapid test available • Self testing is a critical tool in reaching
Slide 25: R&D: Emerging Diseases – Ebola & Zika
R&D: Emerging Diseases – Ebola & Zika Michael Reed, Ph.D Senior Vice President, Research & Development and Chief Science OraSure Technologies, Inc.
Slide 26: Emerging Diseases
Emerging Diseases “An emerging disease is one that has appeared in a population for the first time, or that may have existed previously but is rapidly increasing in incidence or geographic range”… World Health Organization
Slide 27: Ideal solution for emerging disease
Ideal solution for emerging disease • First line of defense is identifying and containing infected populations • Demand for tests is generally small with sudden peaks during outbreaks • Industry-Public Health collaborations critical to providing robust, rapid solutions Powerful OraQuick platform ide
Slide 28: OraQuick EBOLA Rapid Antigen Test
OraQuick EBOLA Rapid Antigen Test 28 28
Slide 29: Quick and collaborative crisis response
Quick and collaborative crisis response 10 month concept to deployment
Slide 30: Impact of Ebola program
Impact of Ebola program Providing high impact solution for Ebola Outbreaks in West Africa Ebola control (since 2014 epidemic) • CDC has 75 staff in Africa to prevent another Ebola epidemic • Cadaver testing is critical for outbreak management • 7 outbreaks since 2014 epidemic have been controlled du
Slide 31: OraQuick ZIKA Rapid Antibody Test
OraQuick ZIKA Rapid Antibody Test 31
Slide 32: The Zika crisis
The Zika crisis “Zika really is unprecedented. Never before have we seen a mosquito-borne virus that can cause birth defects” Dr. Tom Frieden, CDC Director Easy transmission Health effects • Flu-like symptoms: 20% of all infections • Congenital birth defects: ~5% of pregnancies • Guillain-Barre Synd
Slide 33: Significant rise in Zika infections
Significant rise in Zika infections • 67 countries reporting Zika Infections since 2015 • 171K confirmed cases in the Americas alone AFRICA SE ASIA WESTERN PACIFIC AMERICAS SITUATION REPORT: ZIKA VIRUS, MICROCEPHALY, GUILLAIN-BARRÉ SYNDROME -17 NOVEMBER 2016
Slide 34: Zika in the U.S. and territories
Zika in the U.S. and territories Total infections Pregnant women U.S. & D.C.: 4,444 U.S. & D.C.: 1,114 U.S. territories: 32,724 U.S. territories: 2,561 0 1-11 12-22 23-49 50-100 >101 Local vector-borne transmission States & Territories Reporting Zika Disease Solid shading represents travel-associate
Slide 35: Zika health impact
Zika health impact “All pregnant women in the U.S. and U.S. territories should be assessed for possible Zika virus exposure at each prenatal care visit.” ACOG Practice Advisory, October 18, 2016 “Regardless of how WHO defines Zika, it is unprecedented, and it’s an extraordinary risk for pregnant wom
Slide 36: Zika detection needs
Zika detection needs Molecular Serological Unmet need Ricketson (2016) WebMed Central, Mar 24 Protein Data Bank Zika Genome detection Zika IgM detection Zika IgM detection 10 Lab-based EUA tests 2 Lab-based EUA tests Point-of-care rapid test
Slide 37: Awarded $16.6M BARDA contract
Awarded $16.6 M BARDA contract THE WALL STREET JOURNAL YOU ARE READING A PREVIEW OF A PAID ARTICLE SUBSCRIBE NOW TO GET CONTENT.
Slide 38: OraQuick Zika Rapid Antibody Test
OraQuick Zika Rapid Antibody Test* Point-of-care value Rapid results at patient’s side • <30 minute read time • Relieves Public Health Lab testing burden Prototype* data In-house testing with prototype design: • % positive agreement: 97.3% (36/37) • % negative agreement: 98.3% (295/300) Targeting EU
Slide 39: Unique solution for emerging disease
Unique solution for emerging disease Rapid development of high quality tests for outbreak management Robust, flexible & proven platform Strong partnerships and funding 39
Slide 40: Tuberculosis (TB)
Tuberculosis (TB) Cassandra Kelly-Cirino, Ph.D. Vice President, Infectious Disease TB and Emerging Diseases Program Lead DNA Genotek
Slide 41: TB is an ongoing global crisis
TB is an ongoing global crisis . TB KILLS • 4,900 people per day • One person every 18 seconds – 1.8 million died in 2015 – 400,000 people with HIV+TB • 28,500 people are infected per day – 10.4 million people infected in 2015 Better reporting, diagnosis and access to care will close this gap Source
Slide 42: WHO's end TB strategy
WHO’s end TB strategy End the global TB epidemic • Reduce TB deaths by 90% • Cut new cases by 90% between 2015 and 2035 • Ensure that no family is burdened with catastrophic expenses due to TB
Slide 43: Why is TB eradication such a challenge?
Why is TB eradication such a challenge? • Easy to catch – TB is highly contagious – spread through the air, most often by coughing • Difficult to reach patients – Poor patient access – rural settings with no infrastructure – Need to collect, transport and process viable sputum samples • Hard to diag
Slide 44: The crisis gap
The crisis gap • While 6.1 million people had access to quality TB care, 4.3 million missed out in 2016 • 100M sputum samples were collected to find the 6.1 diagnosed cases in 2016 • ~200M sputum samples are needed to find the 4.3M undiagnosed people Source: WHO
Slide 45: Current sample method challenges
Current sample method challenges Current sample method challenges Sample quality • Samples need to be shipped on ice or can be putrefied and unusable when they arrive at the lab • Sample quality directly impacts tests results and diagnosis rates Laboratory inefficiency • NaOH/NALC used to liquefy sa
Slide 46: Our solution
Our solution Leader in Biospecimen Optimization • A reagent designed to maintain MTb viability for 8 days between 39oF and 104oF while liquefying and decontaminating sputum samples. • IP protected Sample transport and • CE/IVD marked decontamination reagent
Slide 47: What OMNIgene SPUTUM solves
What OMNIgene SPUTUM solves • Eliminate need and cost of cold chain transport • Eliminate samples lost due to putrefaction in transit • Eliminate daily reagent preparation and quality control testing • Minimize culture test contamination and failures – Nepal study: Improved TB detection by 9% and de
Slide 48: Market access strategies
Market access strategies #1 Independent Countries, NGO’s & Private Labs • BRICS: BRAZIL, China, India and South Africa •NGO’s MSF, KNCV, FHI360, PHI IOM Private labs:India, South Africa, Latin America #2: Requires WHO Endorsement • For Global Fund Procurement
Slide 49: Funding impact
Funding impact Funding Source BB international LW) -< _ OraSue Technologies, ac, a © More action and investment in these countries will drive down the TB burden
Slide 50: Market access plan
Market access plan In country evaluations to speed adoption upon WHO endorsement Peer reviewed publication data (open independent funding) ->ongoing 3 complete 1 more submitted 2014 2015 2016 2017 2018 CE/IVD registrations Unlock funding (USAID, Global Fund) > WHO endorsement – target Q2 2017 Establ
Slide 51: Our unique advantage
Our unique advantage Technical Validations Publications Collaborations Country wide technical validations in progress Working toward WHO endorsement Collaborating with key stakeholders
Slide 52: -< OraSureTechnlgies, ne.
LW) -< OraSureTechnlgies, ne. —_ 2
Slide 53: Personal Genomics
Personal Genomics Brain Smith Senior Vice President and Business Unit Lead, Molecular DNA Genotek
Slide 54: Genomics: From Double-Helix to Helix
Genomics: From Double-Helix to Helix 1865 Mendel presents research on plant hybridization 1953 Watson & Crick discover the double helix DNA structure 1983 Huntington’s Disease is the first genetic disease mapped 1996 First mammal is cloned 2003 Completion of the Human Genome Project 2006 First DTC i
Slide 55: Exponential growth in genetic testing
Exponential growth in genetic testing
Slide 56: Personal genomics segments
Personal genomics segments 3 E v > o = 3 2 a ° @ ie) 5 ) 3, 9] a raSureTectnlgies, ne. 56
Slide 57: Helix
HELIX BUSINESS INSIDER TECH INSIDER A new $100 million company could transorm the way we interact with our own DNA One sequence Limitless learning Source: www.Helix.com
Slide 58: 23andMe genotypes one millionth customer
23andMe 23andMe Genotypes One Millionth Customer Direct-to-Consumer Genetic Testing Company Reaches Milestone; Increases Potential for Genetic Research 58 Source: www.23andMe.com
Slide 59: Growing worldwide market opportunity
Growing worldwide market opportunity THE GLOBAL PLATFORM FOR GENOMIC BIG DATA WuXi NextCODE is a genomic information company using sequence data to improve health for people around the world.
Slide 60: Enabling personal genomics
Enabling personal genomics Access to patients/consumers No established collection infrastructure Competing with reference labs Reference labs • Established brick and mortar service clinics for sample collection Emerging Personal Genomics companies • In clinic or at home access to patients for sample
Slide 61: The sample enables scalability
The sample enables scalability Easy to collect, non-invasive • By individuals at home or at point of care • By children and the elderly • By clinicians Reliable • Usability lowers failure rates High quality • Increasing trend toward sequencing • Leverage data across evolving test Compatible with exi
Slide 62: Proven solutions
Proven solutions First and only FDA 510(k) cleared devices Leader in Biospecimen optimization Oragene Dx and ORAcollect Dx are the only FDA 510(k) cleared devices• proven for collection, stabilization and ambient temperature transportation and storage of DNA from saliva. • FDA cleared for in vitro d
Slide 63: Our unique advantage
Our unique advantage • Customizations • Donor recruitment • Logistical support • Single Order Fulfillment Products CustomersService and support Regulatory and quality focus Collaborating with leaders and innovators in the space End-to-end service and support 63
Slide 64: Microbiome
Microbiome Aaron Del Duca Vice President, Technology and Microbiome Program Lead DNA Genotek G J Q
Slide 65: What is the Microbiome?
What is the Microbiome? The human-associated microbiome comprises the trillions of micro organisms that live on us and in us.
Slide 66: Genomics vs. Metagenomics
Genomics vs. Metagenomics Genomics Metagenomics • 23,000 genes • 1000 species identified (gut) • 10M SNPs • Collectively, 10M genes • Humans share 99.5% • More or less static in ‘core’• Dynamic Missing Heritability? 16S rRNA Seq Shotgun Exome Seq Metagenomics WGS • 40-70% consistently appear
Slide 67: Value of microbiome-enabled discovery
Value of microbiome-enabled discovery 3 years Progression to Type 1 Diabetes in infants Genes don’t tell the whole story! Longitudinal monitoring essential to understand chronic disease progression A. Kostic, D. Gevers, R. Xavier, et al. Cell Host Microbe 2015 Feb 11;17(2):260-73
Slide 68: Microbiome impact to healthcare
Microbiome impact to healthcare • It influences extremely high burden/high value medical conditions – Gastrointestinal diseases, Type 1&2 Diabetes, Skin conditions, the urinary tract, women’s health and neonatal health • It provides a means of intercepting disease and personalizing treatments – Diag
Slide 69: Early stage, rapid growth opportunity
Early stage, rapid growth opportunity Fiscal Year Genomics Projects Funding Fiscal Year Microbiome Projects Funding 2011 4,955 $ 3,081,216,026 2012 5,314 $ 3,442,245,767 2013 5,436 $ 3,430,237,569 2013 344 $ 205,755,751 2014 5,573 $ 3,677,078,245 2015 5,370 $ 3,664,397,258 2014 478 $ 327,853,816 201
Slide 70: Leverages population research infrastructure
Leverages population research infrastructure * • Overlaying Human Genome Project completion with Human Microbiome Project completion reveals that the Microbiome research field is growing at least as quickly as genomics. • Best model for Microbiome business is Human Genomics business. Slightly smalle
Slide 71: Quickly translating to industry applications
Quickly translating to industry applications Over $1.5B in Venture Capital invested into microbiome start-ups since 2012 http://www.wsj.com/articles/microbiome-companies-attract-big-investments-1474250460
Slide 72: Constrained by methods and reproducibility
Constrained by methods and reproducibility • M • Y • Y • K “The inter-lab comparability of measurements on microbiomes is generally poor.”
Slide 73: Biospecimen quality dictates data quality
Biospecimen quality dictates data quality * * * • Human-factors driven design • Ambient temperature stable • Pristine representation of in vivo microbiome • Scalable for high throughput processing *For research use only
Slide 74: Positioned to leverage strengths
Positioned to leverage strengths DNA Genotek customers * * * * • FDA cleared for in vitro diagnostic use with the eSensor Warfarin Sensitivity Saliva Test * For research use only
Slide 75: Root of the reproducibility challenge
Root of the reproducibility challenge 1.00 0.75 0.50 0.25 Study Design 0.00 Sequencing Wth oge on B hodsiliz Donor onor • N = 30 donors • Collected • Extracted in triplicate • Sequenced • Error is additive! Bray-Curtis Distance
Slide 76: Establishing the new gold standard
Establishing the new gold standard 1.00 0.75 0.50 0.25 0.00 E. L. Anderson, K. Nelson, M. Jones, et al. (2016) Nature Sci Rev D. Zeevi, E. Elinav, E. Segal, et al. (2015) Cell Snap freezing S. J. Song, R. Knight, et al. Home Brew 1 (2016) mSystems Home Brew 2 Home Brew 3 Results: Based on our analys
Slide 77: Constrained by methods and reproducibility
Constrained by methods and reproducibility Constrained by methods and reproducibility Key challenges: • Standardized wet lab protocols, high-throughput processing • Validated bioinformatics pipelines • Longitudinal and functional studies • Patient engagement, standardized phenotyping and metadata ca
Slide 78: Turn-key services from sample to signal
Turn-key services from sample to signal T Z U M Y M Optimal SamplingStudy Design & Biomarker Discovery Structured DataEnhanced Engagement 2 -Way Communication
Slide 79: Microbiome impact on personalized medicine?
Microbiome impact on personalized medicine? Cell, Volume 163, Issu 5, p1079-19 November 2015 E. Segal, E. Elinav, D. Ze’evi, et al. E. Segal, E. Elinav, D. Ze’evi, et al. Microbiome impact on personalized medicine? Cell, Volume 163, Issue 5, p1079–1094, 19 November 2015 • Significant difference betw
Slide 80: Our unique advantage
Our unique advantage End-to-end service and support Technical validation of sample quality to results Leveraging leadership position in academic market • Study Design • Customizations E. L. Anderson, K. Nelson, • Donor recruitment M. Jones, et al. • Logistical support (2016) Nature Sci Rev • Interna
Slide 81: R&D: Sample Optimization
R&D: Sample Optimization Rafal Iwasiow, Ph.D. Vice President R&D Molecular DNA GEnotek
Slide 82: Sample quality is paramount
Sample quality is paramount Sample quality is paramount “We now have the technical ability to get the wrong answers with unprecedented speed. If we put the wrong stuff into the front end of our analytical pipeline, we will not only lose the war on cancer, we’ll pollute the scientific + literature wi
Slide 83: Our current solutions – optimized samples
Our current solutions – optimized samples optimized samples Leader in Biospecimen Optimization • Easy and reliable collection • Stabilize and protect the in vivo state • Ship and store at ambient temperature • Integrate into lab protocols and automation • High quality DNA/RNA for all applications •
Slide 84: Proven platforms accelerate growth
Proven platforms accelerate growth Molecular Platforms Combined physical design and reagent to optimize products to address market needs 2004 2011 2005 2006 2007 20102002 2008 2009 2012 2013 2014 2015 2016 2017 • FDA cleared for in vitro diagnostic use with the eSensor Warfarin Sensitivity Saliva Te
Slide 85: Rapid innovation to meet customer needs
Rapid innovation to meet customer needs * * * For research use only in the United States. OMNIgene®•Gut (OM-200), Oragene (OG-500/OG-575/OG-600/OG-675) and OMNIgene®•Sputum are CE marked for In Vitro Diagnostic Use and not available for sale in the U.S.A.
Slide 86: Sequencing and multi-sample challenges
Sequencing and multi-sample challengs Biological samples are diverse and complex % Microbial DNA % Human DNA How to stabilize the sample? • We approach it from the diverse biological perspective of each sample type • Take control of the environment = take biology out of the equation – Disrupt cells
Slide 87: Oragene as a source of DNA for WGS
Oragene as a source of DNA for WGS AGBT 2016 Poster – Broad Institute “To date, we have sequenced over 1585 saliva (Oragene) samples to 30x coverage using the HiSeqX.” “The alignment rates to human suggest bacterial contamination levels ranging from 0-80% with an average of 10%. Given this experienc
Slide 88: New platform opportunity
New platform opportunity Y K K T New platform opportunity Targeted market solutions for optimized sequencing workflow Upsell for existing customers
Slide 89: Optimizing samples for sequencing
Optimizing samples for sequencing 100 80 60 40 20 0 Sputum Saliva Feces Human Bacteria ID Market Microbial Benefits/ drivers • Optimize for sequencing Genomics Depletion • Standardize NGS workflows • Enable NGS applications for low bacterial biomass samples Microbiome Enrichment • Optimize for seque
Slide 90: Financial Review / Business Development
Financial Review / Business Development Ron Spair Chief Operating Officer and Chief Financial Officer
Slide 91: Business development program
Business development program Over $120 million in cash and marketable securities and no debt Our criteria: • Seeking opportunity to in-license, partner or acquire a product or company that complements or leverages our existing business • Focused on sample prep, enrichment, collection, microbiome and
Slide 92: Quarterly cash/cash equivalents
Quarterly cash/Cash equivalents Q1-2014 – Q3-2016 actual (MUSD) $130 $110 $90 $70 $50 Q1 ‘14 Q2 ‘14 Q3 ‘14 Q4 ‘14 Q1 ‘15 Q2 ‘15 Q3 ‘15 Q4 ‘15 Q1 ‘16 Q2 ‘16 Q3 ‘16 $84.2 $80.3 $94.4 $92.4 $89.5 $91.3 $108.2 $101.3 $102.2 $113.4 $121.2
Slide 93: YOY cash flow from operations
YOY Cash flow from Operations 2012 actual – Q3 -2016 (MUSD) $30 $10 ($10) ($5.4) $8.4 $7.5 $15.8 $23.4 2012 2013 2014 2015 2016 YTD as of 9/30/16
Slide 94: ID business development strategy
ID business development strategy Infectious Disease strategies drive specific business development opportunities to investigate: • Technology to enhance current lateral flow devices (e.g. digital reader, assay, technology licenses) • Technologies to expand point of care testing portfolio (lateral fl
Slide 95: Molecular business development strategy
Molecular business development strategy Molecular business strategies drive specific business development needs to investigate: • Collection, stabilization, enrichment and prep technologies that are disruptive and enable innovation in NGS market (small volume blood, liquid biopsy, sample to sequence
Slide 96: Executing strategies for growth
Executing strategies for growth Growth Market Opportunities Innovation Proven platforms Leadership Strong partnerships, funding and collaborations HIV HCV TB Emerging Diseases Personal Genomics Microbiome
Slide 97: -< OraSureTechnlgies, ne.
LW) -< OraSureTechnlgies, ne. —_ 7
Slide 98: Additional information
Additional information LW) -< OraSureTechnlgies, ne. a
Slide 99: Glossary
Glossary BARDA: Biomedical Advanced Research and Development Authority FIND: Foundation for Innovative New Diagnostics GDF: Global Drug Facility IgM: Immunoglobulin M IOM: International Organization for Migration KNCV: Royal Netherlands Chemical Society MSF: Doctors without Boarders NGO: Non-Governm